{"id":2123,"date":"2020-11-06T13:05:13","date_gmt":"2020-11-06T12:05:13","guid":{"rendered":"https:\/\/www.maiwald.eu\/all\/presseberichte\/royalty-pharma-and-biohaven-announce-funding-agreement-totaling-up-to-450-million-royalty-pharma\/"},"modified":"2021-10-04T16:29:18","modified_gmt":"2021-10-04T14:29:18","slug":"royalty-pharma-and-biohaven-announce-funding-agreement-totaling-up-to-450-million-royalty-pharma","status":"publish","type":"presseberichte","link":"https:\/\/www.maiwald.eu\/en\/press-coverage\/royalty-pharma-and-biohaven-announce-funding-agreement-totaling-up-to-450-million-royalty-pharma\/","title":{"rendered":"Royalty Pharma and Biohaven Announce Funding Agreement Totaling up to $450 Million (Royalty Pharma)"},"content":{"rendered":"\n<ul class=\"wp-block-list\"><li>\u200b\u200b\u200b\u200b\u200b\u200bBiohaven will receive up to $250 million to fund zavegepant\u2019s development in migraine and non-migraine indications<\/li><li>Royalty Pharma to acquire up to a 3% royalty for zavegepant, a 0.4% royalty of Nurtec<span class=\"smaller\"><sup>TM<\/sup><\/span>&nbsp;ODT and success-based milestone payments<\/li><li>Royalty Pharma will purchase new Commercial Launch Preferred Equity from Biohaven for a total of $200 million payable between 2021 and 2024, providing additional funding for its CGRP-targeting franchise<\/li><\/ul>\n\n\n\n<p>Cooley acted as legal advisor to Biohaven on the transaction. Goodwin Procter, Jones Day and Maiwald acted as legal advisors to Royalty Pharma.<\/p>\n\n\n\n<p>This text is a <a href=\"https:\/\/www.royaltypharma.com\/news-releases\/news-release-details\/biohaven-and-royalty-pharma-announce-funding-agreement-totaling\" target=\"_blank\" rel=\"noopener\">press release from Royalty Pharma<\/a>.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2123","presseberichte","type-presseberichte","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte\/2123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte"}],"about":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/types\/presseberichte"}],"version-history":[{"count":1,"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte\/2123\/revisions"}],"predecessor-version":[{"id":9473,"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/presseberichte\/2123\/revisions\/9473"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/media?parent=2123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}